FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 333:597-599 August 31, 1995 Number 9 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Nathan, D. G. Related Article by Olivieri, N. F. PubMed Citation

To the Editor: Olivieri et al. (April 6 issue)¹ are to be congratulated on their work on deferiprone, which, in addition to demonstrating the drug's efficacy in iron chelation, is the only study so far to have addressed some of the controversies surrounding the use of the drug.^2,3,4,5

Our experience with autoimmune phenomena has not been confined to just one case of fatal drug-induced systemic lupus erythematosus.² We have found a significantly higher incidence of antinuclear antibodies in patients with thalassemia treated with deferiprone (7 of 27) than in those not receiving the drug (2 of 63, P<0.01). Antibodies to . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.